The potential use of monoclonal antibodies and other novel agents as drugs to lower LDL cholesterol

Author： Blom Dirk J   Marais Adrian David   Raal Frederick J   Lambert Gilles  

Publisher： Future Medicine

ISSN： 1758-4299

Source： Clinical Lipidology, Vol.8, Iss.2, 2013-04, pp. : 243-256

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Effect of the Market Withdrawal of Carisoprodol on Use of Other Prescribed Drugs With Abuse Potential

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 91, Iss. 3, 2012-03 ,pp. : 438-441

John Wiley & Sons Inc

Access to resources Recommend Favorite

High LDL cholesterol and statin use were independently associated with lower eight-year mortality in a cohort free from terminal illness, cardiovascular disease, and diabetes at baseline

By Thulesius Hans  

Scandinavian Journal of Primary Health Care, Vol. 32, Iss. 1, 2014-03 ,pp. : 1-2

Informa Healthcare

Access to resources Recommend Favorite

Monoclonal Antibodies against the CεmX Domain of Human Membrane-Bound IgE and Their Potential Use for Targeting IgE-Expressing B Cells

By  

International Archives of Allergy and Immunology, Vol. 128, Iss. 4, 2002-09 ,pp. : 315-324

Karger

Access to resources Recommend Favorite

Physical activity, body mass index, lipid lowering agents, and LDL cholesterol levels in secondary prevention of CHD

By König Daniel   Müller H.M   Schmidt‐trucksaess A   Berg Aloys  

European Journal of Sport Science, Vol. 2, Iss. 4, 2002-08 ,pp. : 1-10

Taylor & Francis Ltd

Access to resources Recommend Favorite

Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer

By  

CANCER, Vol. 120, Iss. 5, 2014-03 ,pp. : 624-632

John Wiley & Sons Inc

Access to resources Recommend Favorite